DUBLIN, Ireland, May 21, 2024 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today the appointment of Naseem Amin, M.D. to its board of directors, effective May 17, 2024. Dr. Amin, a highly successful executive who brings global industry and leadership experience to Avadel, currently serves as Chief Executive Officer of Orphalan SA. “On behalf of the entire Avadel team, we are excited to welcome Dr. A ...

Avadel Pharmaceuticals plc (NASDAQ:AVDL) Q1 2024 Earnings Conference Call May 8, 2024 8:30 AM ET Company Participants Austin Murtagh - Director at Stern Investor Relations Gregory Divis - CEO Richard Kim - Chief Commercial Officer Thomas McHugh - CFO Conference Call Participants Andrew Tsai - Jefferies François Brisebois - Oppenheimer Ami Fadia - Needham & Company David Amsellem - Piper Sanger Marc Goodman - Leerink Partners Ashwani Verma - UBS Oren Livnat - H.C. Wainwright Chase Knickerbocker - Craig Hallu ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ——————— Title of each class Trading Symbol(s) Name of each exchange on which registered Ordinary Shares, nominal value $0.01 per share AVDL The Nasdaq Global Market FORM 10-Q ——————— ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period ...

Exhibit 99.1 Avadel Pharmaceuticals Provides Corporate Update and Reports First Quarter 2024 Financial Results -- Generated $27.2 million in net revenue from sales of LUMRYZ™ -- -- Through March 31, greater than 2,800 patients enrolled in Avadel's RYZUP patient support services and more than 1,700 patients initiated therapy -- -- Pursuing expansion opportunities for LUMRYZ with sNDA in pediatric narcolepsy; on track to enroll first patient in a Phase 3 pivotal idiopathic hypersomnia trial in the second half ...

DUBLIN, Ireland, May 01, 2024 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (NASDAQ:AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that it will host a conference call and live webcast at 8:30 a.m. ET on Wednesday, May 8, 2024, to provide a corporate update and discuss the Company's financial results for the first quarter ended March 31, 2024. To access the conference call, investors are invited to dial +1 (800) 715-9871 (U.S. and Canada) or +1 (646) ...

Avadel (AVDL) closed the last trading session at $17.81, gaining 5.5% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $22.90 indicates a 28.6% upside potential.The average comprises 10 short-term price targets ranging from a low of $19 to a high of $29, with a standard deviation of $3. While the lowest estimate indicates an increase of 6.7% from the current price level, the most op ...

miniseriesThesis on AVDL: Maintaining a Buy Rating Q4 2023 Earnings and Commercial Performance of Lumryz We update readers based on FY 2023 earnings print and litigation update, where we carefully evaluated our thesis and decided to maintain our buy rating on AVDL (our latest analysis). Avadel Pharmaceuticals reported its Q4 2023 earnings, highlighting the commercial traction of Lumryz, its novel once-nightly formulation of sodium oxybate for narcolepsy. We believe the earnings are positive based on the ...

DUBLIN, Ireland, March 05, 2024 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that members of management will participate in the following upcoming investor conferences: Leerink Global Biopharma Conference: Fireside chat on Monday, March 11 at 3:20 p.m. ET.UBS Virtual CNS Day: Fireside chat on Monday, March 18 at 12:30 p.m. ET. A live webcast of these events, as well as an archived recordings, ...

DUBLIN, Ireland, March 04, 2024 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (NASDAQ:AVDL), today issued a statement in response to a jury ruling from the United States District Court for the District of Delaware ("Court") in a patent suit brought by Jazz Pharmaceuticals Inc. regarding LUMRYZ™. Avadel is pleased with the jury's decision ruling in favor of Avadel with respect to one of the contested patents. As it relates to the jury's decision against Avadel regarding the additional contested patent, the ...

Avadel Pharmaceuticals plc (NASDAQ:AVDL) Q4 2023 Earnings Conference Call March 4, 2024 7:30 AM ET Company Participants Austin Murtagh - Stern IR Gregory Divis - CEO Richard Kim - Chief Commercial Officer Thomas McHugh - CFO Conference Call Participants Francois Brisebois - Oppenheimer Ami Fadia - Needham Andrew Tsai - Jefferies David Amsellem - Piper Sandler Ashwani Verma - UBS Myriam Belghiti - LifeSci Capital Chase Knickerbocker - Craig-Hallum Rudy Li - Leerink Matt Kaplan - Ladenburg Thalmann Oren Livna ...